Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.

European journal of clinical pharmacology - 1 Nov 1999

Vandel P, Haffen E, Vandel S, Bonin B, Nezelof S, Sechter D, Broly F, Bizouard P, Dalery J

Abstract excerpt

OBJECTIVE: Among Caucasians, a lack of cytochrome P450 enzyme CYP2D6 is observed in 5-10% of individuals, named poor metabolizers (PMs). A consequence may be an impaired metabolism of many drugs such as most of the psychotropic drugs with an increased risk of drug side effects. This enzyme is also involved in the metabolism of endogenous compounds, including neurotransmitters such as dopamine and dopamine-related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Basal Ganglia Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Dextromethorphan

Share to Excitatory Amino Acid Antagonists

Share to Polymerase Chain Reaction

Share to Polymorphism, Restriction Fragment Length

Share to White People

Source

Identifiers

PMID: 10638395
DOI: 10.1007/s002280050689

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.PMID 10638395Read ↗

Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].Semantic proximity Read ↗

Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.Semantic proximity Read ↗

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implicationSemantic proximity Read ↗

CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.Semantic proximity Read ↗

Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.Semantic proximity Read ↗

A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.Semantic proximity Read ↗

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.Semantic proximity Read ↗

Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.Semantic proximity Read ↗

CYP2D6 phenotyping with dextromethorphan.Semantic proximity Read ↗

CYP2D6 genotype and phenotype relationship in South Indians.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.